INS and diabetes mellitus: Nevertheless, a recent study using linagliptin (a DPP4 inhibitor) for the treatment of an adolescent patient with WS1 diabetes in addition to intensive insulin treatment, showed a dramatic decrease in exogenous insulin need with a good safety profile [70].